The Lung Cancer Assays Panel detects CEA, CYFRA21-1, and NSE tumor markers which are used for monitoring the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma, and small-cell lung cancer, respectively. The panel also detects ProGRP which is a useful marker in SCLC, demonstrating association with survival in NSCLC and SCLC limited to univariate analysis, and detects SCCA which has been confirmed to be closely related to the prognosis of lung cancer, especially squamous cell carcinoma.